TAK TAKEDA PHARMACEUTICAL CO LTD IFRS Annual reports only
Pharmaceutical Preparations · NYSE · SEC CIK 1395064 · Reporting currency JPY
Financial factors as of 2025-03-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: JPY | FY20252025-03-31 | FY20242024-03-31 | FY20232023-03-31 | FY20222022-03-31 | FY20212021-03-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | 4.58T | 4.26T | 4.03T | 3.57T | 3.20T |
| Cost of revenue | 1.58T | 1.43T | 1.24T | 1.11T | 994.31B |
| Gross profit | 3.00T | 2.84T | 2.78T | 2.46T | 2.20T |
| R&D expense | 730.23B | 729.92B | 633.33B | 526.09B | 455.83B |
| Operating income | 342.59B | 214.07B | 490.50B | 460.84B | 509.27B |
| Interest expense | 137.31B | 119.53B | 116.97B | 122.43B | 130.81B |
| Pretax income | 175.08B | 52.79B | 375.09B | 302.57B | 366.24B |
| Income tax | 66.94B | -91.41B | 58.05B | 72.41B | -9.94B |
| Net income | 107.93B | 144.07B | 317.02B | 230.06B | 376.00B |
| EBITDA | 1.10T | 942.08B | 1.15T | 1.04T | 1.07T |
| EPS (basic) | 68.36 | 92.09 | 204.29 | 147.14 | 240.72 |
| EPS (diluted) | 67.23 | 91.16 | 201.94 | 145.87 | 238.96 |
| Weighted avg. shares (diluted) | 1.61B | 1.58B | 1.57B | 1.58B | 1.57B |
| Balance sheet | |||||
| Cash & equivalents | 385.11B | 457.80B | 533.53B | 849.70B | 966.22B |
| Receivables | 709.47B | 668.40B | 649.43B | 696.64B | 783.09B |
| Inventory | 1.22T | 1.21T | 986.46B | 853.17B | 753.88B |
| Current assets | 2.52T | 2.56T | 2.40T | 2.59T | 2.71T |
| PP&E, netmay include right-of-use assets (IFRS) | 1.97T | 1.99T | 1.69T | 1.58T | 1.45T |
| Goodwill | 5.32T | 5.41T | 4.79T | 4.41T | 4.03T |
| Intangibles | 3.63T | 4.27T | 4.27T | 3.82T | 3.91T |
| Total assets | 14.25T | 15.11T | 13.96T | 13.18T | 12.91T |
| Current liabilities | 2.51T | 2.31T | 2.48T | 2.15T | 1.77T |
| Short-term debt | 548.94B | 367.25B | 339.60B | 203.99B | 22.15B |
| Long-term debt | 3.97T | 4.48T | 4.04T | 4.14T | 4.61T |
| Total debt | 4.52T | 4.84T | 4.38T | 4.35T | 4.64T |
| Total liabilities | 7.31T | 7.83T | 7.60T | 7.49T | 7.74T |
| Shareholders' equity | 6.94T | 7.27T | 6.35T | 5.68T | 5.17T |
| Net debt | 4.13T | 4.39T | 3.85T | 3.50T | 3.67T |
| Shares outstanding | 1.59B | 1.58B | 1.58B | 1.58B | 1.58B |
| Cash flow statement | |||||
| Operating cash flow | 1.06T | 716.34B | 977.16B | 1.12T | 1.01T |
| Capital expenditure | 200.79B | 175.42B | 140.66B | 123.25B | 111.21B |
| Free cash flow | 856.39B | 540.92B | 836.50B | 999.85B | 899.73B |
| Investing cash flow | -367.06B | -463.86B | -607.10B | -198.12B | 393.53B |
| Financing cash flow | -751.42B | -354.42B | -709.15B | -1.07T | -1.09T |
| Depreciation & amortization | 761.40B | 728.00B | 664.40B | 583.15B | 559.67B |
| Dividends paid | 302.50B | 287.19B | 279.42B | 283.67B | 283.36B |
| Share buybacks | 51.86B | 2.33B | 26.93B | 77.53B | 2.14B |
Free plan shows the latest 5 periods; Pro shows all 9 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· Amounts are in the company's reporting currency, JPY, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.